SMARCB1 and breast carcinoma: Accordingly, RB1CC1 itself and/or molecules (such as p53, SNF5 and PIASy) involved in the RB1CC1-RB1 pathways may be effective biomarkers to evaluate the clinical status of breast cancer patients.